Akero Therapeutics: Strong Financial Health and Promising Clinical Data Justify Buy Rating

Analyst Rami Katkhuda from LifeSci Capital maintained a Buy rating on Akero Therapeutics (AKRO – Research Report) and keeping the price target at $80.00.

Rami Katkhuda has given his Buy rating due to a combination of factors related to Akero Therapeutics’ promising financial and clinical outlook. The company reported strong first-quarter earnings with over $1.128 billion in cash and equivalents, which is expected to support operations until 2028. This financial stability is complemented by positive clinical trial results, particularly from the Phase IIb SYMMETRY study, which showed significant improvements in fibrosis for patients with MASH over a 96-week period.
Furthermore, the EFX treatment has demonstrated consistent benefits across various patient demographics, including those with diabetes and cryptogenic cirrhosis, as well as those on statins and GLP-1 analogs. The ongoing SYNCHRONY pivotal program is expected to further validate these findings, with data anticipated in the coming years. The combination of financial health and promising clinical data underpins the confidence in Akero Therapeutics’ potential for growth, justifying the Buy rating.

In another report released today, Citi also maintained a Buy rating on the stock with a $80.00 price target.

Based on the recent corporate insider activity of 116 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AKRO in relation to earlier this year.